Recent Quotes (30 days)

You have no recent quotes
chg | %

Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 187   

Articles published

BMY 63.36 +0.01 (0.02%)
price chart
Glistening Stock's Review – Bristol-Myers Squibb Company (NYSE:BMY)
On Friday, Shares of Bristol-Myers Squibb Company (NYSE:BMY) expressed a change of -0.26% and is currently trading at $63.17.
Buy or Sell? What Analysts Recommends: SunPower Corporation (SPWR), Bristol ...  StockNewsJournal
Trading Statistics of Bristol-Myers Squibb Company (BMY)  AppsforPCdaily
(nivolumab) Receives FDA Approval for the Treatment of Hepatocellular ...
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection for intravenous use for the treatment of patients with ...
Bristol-Myers Squibb (BMY) Granted Approval by Japanese Ministry of Health ...  StreetInsider.com
Bristol-Myers Squibb says late-stage cancer drug combination study met ...
Bristol-Myers Squibb Co. BMY, -0.02% said early Thursday that a late-stage clinical trial for cancer drugs Opdivo and Yervoy in patients with previously untreated advanced or metastatic renal cell carcinoma showed better overall survival compared to ...
Bristol-Myers Squibb Co. (BMY) PT Raised to $65 at Goldman Sachs, Positively ...  StreetInsider.com
Bristol-Myers Squibb to Announce Results for Third Quarter 2017 on October 26  Business Wire (press release)
Buy Bristol-Myers Squibb Co (BMY) Stock With No Fear
Bristol-Myers Squibb Co (NYSE:BMY) stock has had a tumultuous 12-month period. In January, it fell 20% but luckily for the bulls it recovered all of it within five weeks.
Opdivo In Focus After BMY's Checkmate-214 Study Being Stopped Early  Forbes
Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb  Motley Fool
AbbVie (ABBV), Bristol-Myers Squibb (BMY) Announce Pact to Evaluate ...
AbbVie (NYSE: ABBV) and Bristol-Myers Squibb Company (NYSE: BMY) today announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's immunotherapy ...
Shares Trading unchanged at $87.41 (ABBV) AbbVie and Bristol-Myers Squibb ...  HugoPress
AbbVie to trial ABBV-399 in combo with Opdivo  The Pharma Letter (registration)
UPDATE 1-Bristol-Myers, Daiichi Sankyo to test Opdivo combo for cancers
Aug 28 (Reuters) - Bristol-Myers Squibb Co and Daiichi Sankyo said they were evaluating a combination of Bristol-Myers' immuno-oncology drug, Opdivo, with the Japanese company's experimental drug in patients with breast and bladder cancers.
Bristol-Myers, Daiichi Sankyo to test combo therapy for breast, bladder cancers  Nasdaq
Bristol-Myers Squibb and Daiichi Sankyo Announce Research Collaboration to ...  Business Wire (press release)
Halozyme to license drug delivery tech to Roche, Bristol-Myers
(Reuters) - U.S. drugmaker Halozyme Therapeutics Inc said on Thursday it would license its drug delivery technology to Bristol-Myers Squibb Co and Swiss drugmaker Roche in separate collaborations. Shares of Halozyme rose 12.7 percent to $14.85 in ...
Bristol-Myers Squibb and Halozyme Enter Global Collaboration and License ...  Business Wire (press release)
State Street Corp Raises Stake in Bristol-Myers Squibb Company (BMY)  The Ledger Gazette
Halozyme's stock soars after Bristol-Myers license deal
Shares of Halozyme Therapeutics Inc. HALO, -0.48% rocketed 13% in premarket trade Thursday, after the biotechnology company announced a license agreement with Bristol-Myers Squibb Co. BMY, -0.25% to develop subcutaneously administered ...
Bristol-Myers Squibb Company (BMY) stock RSI 73.96 signaled a sell opportunity
Analyzing the technical facts, Bristol-Myers Squibb Company (BMY)'s current distance from 20-Day Simple Moving Average is 4.64% and standing 9.74% away from 50-Day Simple Moving Average while traded up 13.81% from 200-Day Simple Moving ...
Which Way Traders Signposts Avon Products, Inc. (AVP), Bristol-Myers Squibb ...  StockNewsJournal
Bristol-Myers Squibb Company (BMY): What Does The Future Look Like?  Simply Wall St
Bristol-Myers Squibb Announces Dividend
NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-nine cents ($0.39) per share on the $.10 par value Common Stock of the corporation.
Bristol-Myers Squibb Company (BMY) Shares Bought by Pinnacle Associates Ltd.  The Ledger Gazette
A Glimpse Into Insider Trading And Ownership At Bristol-Myers Squibb Company ...  Economic News